Key facts
- This page summarizes Frazier Life Sciences VIII, L.P.'s Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Oct 2023, 16:09.
Frazier Life Sciences VIII, L.P. - 24 Oct 2023 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ARQT
- Reported as of
- 24 Oct 2023
- Net transaction value
- +$200,000
- SEC form
- 4
- Accepted by SEC
- 26 Oct 2023, 16:09:29 UTC
- Prior SEC filing
- 09 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- Frazier Life Sciences VIII, L.P., By: FHM Life Sciences VIII, L.P., its general partner, By: FHM Life Sciences VIII, L.L.C., its general, partner, By: /s/ Steve R. Bailey, Chief Financial Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Frazier Life Sciences VIII, L.P. filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 26 Oct 2023.
Change
- Previous filing in this sequence was filed on 09 Aug 2022.
- Current net transaction value: +$200,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARQT
transaction
Common Stock
Purchase
- Transaction value
- $200,000
- Shares
- +80,000
- Change %
- +0.92%
- Price
- $2.50
- Shares after
- 8,764,232
- Date
- 24 Oct 2023
- Ownership
- Direct
ARQT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7
- Date
- 24 Oct 2023
- Ownership
- FHM Life Sciences VIII, L.L.C.
- Footnotes
- F1
ARQT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,266
- Date
- 24 Oct 2023
- Ownership
- By Topper Group II LLC
- Footnotes
- F2
ARQT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 19,381
- Date
- 24 Oct 2023
- Ownership
- By Topper Family Revocable Trust
- Footnotes
- F3
ARQT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 23,688
- Date
- 24 Oct 2023
- Ownership
- By The Heron Living Trust 11/30/2004
- Footnotes
- F4
ARQT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,687
- Date
- 24 Oct 2023
- Ownership
- By Patrick J. Heron
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Frazier Life Sciences VIII, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 5 footnotes
Footnote F1
Represents shares held of record by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron are the sole managing members of FHM Life Sciences VIII, L.L.C. and share voting and investment power of the securities held by FHM Life Sciences VIII, L.L.C. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Footnote F2
Dr. Topper is a manager of Topper Group II LLC and shares voting and investment power over the shares held by Topper Group II LLC.
Footnote F3
Dr. Topper is a trustee of the Topper Family Revocable Trust and has voting and investment power over the shares held by Topper Family Revocable Trust.
Footnote F4
Mr. Heron is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004.
Footnote F5
Includes 4,375 Restricted Stock Units ("RSUs"). Mr. Heron is entitled to receive one (1) share of the Issuer's Common Stock for each one (1) RSU upon the vesting thereof.